Study Enrollment


Your details will not be published or shared.

Clinical Trial

(KEYLYNK-010) A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy

The purpose of this study is to see if pembrolizumab in combination with olaparib helps patients live longer. Some other reasons for conducting this study are to test the safety of pembrolizumab (MK-3475) in combination with olaparib when compared to standard of care hormonal medicine, see how well pembrolizumab in combination with olaparib works when compared to standard of care hormonal medication and see if pembrolizumab in combination with olaparib helps patients have a better quality of life.


Eligibility Criteria

  • Patients must be 18 years of age or older Has confirmed metastatic prostate cancer without small cell histology Has prostate cancer progression while receiving androgen deprivation therapy (or post bilateral orchiectomy) within 6 months prior to screening Has disease that progressed during prior treatment with abiraterone acetate OR enzalutamide, but not both Has received no more than 1 previous chemotherapy regimen for mCRPC

Contact Information

    Kelly Jenkins, RN, MSN, CNL

    (706) 721-1206

   kejenkins@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.